In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Rocket Pharmaceuticals, with a price target of $9.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors including Rocket Pharmaceuticals’ regained momentum and strategic progress in their pipeline. The company has achieved significant milestones such as aligning with the FDA to resume the pivotal Phase 2 trial for RP-A501 in Danon disease, and the FDA’s acceptance of the BLA resubmission for KRESLADI for LAD-I, which is a positive indicator for future approvals.
Additionally, Rocket Pharmaceuticals has shown disciplined execution and strategic focus across its cardiovascular portfolio, with continued FDA engagement on RP-A601 and the initiation of a Phase 1 study for RP-A701. The company’s financial position is also strong, with cash and investments providing an operational runway into Q2 2027, which supports its ongoing and future projects. These factors collectively contribute to the positive outlook and the Buy rating for Rocket Pharmaceuticals’ stock.